2018 Trigeminal Neuralgia Drug Development- Pipeline Analysis Report
Trigeminal neuralgia is one of the most painful clinical conditions causing sudden, intense, recurrent pain usually on one side of face supplied with trigeminal nerve. It affects around 65 to 275 thousand population in the US. The intense pain is evoked by activities affecting the nerve such as talking, eating, smokng etc. Mouth, face and scalp are affected areas.
Trigeminal Neuralgia pipeline comprises of 9 active drugs under active development as of April 2018. Of these, 4 drugs are in phase 2. Further, 4 drugs are in Pre-clinical stage and 1 drug in research stage.
17 companies are developing the pipeline for Trigeminal Neuralgia. Of this, Biogen Inc and Capnia, Inc. have received orphan drug status for their therapeutic candidates.
To assist researchers and business development managers, VPA Research has come up with a comprehensive report on Trigeminal Neuralgia pipeline. The report provides insights into different therapeutic candidates in preclinical, research, discovery, NDA/IND, pre registration, phase 1, phase 2, and phase 3 trials). Drugs under development directly and through combination with other drugs are also included.
Current status, developmental phase, participating companies and entities, recent developments, orphan drug/fast track/other designations, drug class are provided for each Trigeminal Neuralgia pipeline product. Mechanism of Action and the target area of the pipeline product are also provided. Further, clinical and preclinical trials along with results of the trials are also included in the report.
In addition to complete details of each product, the report provides key trends in Trigeminal Neuralgia pipeline studies. The products under development are categorized according to their development phase, mechanism and company to provide detailed insights into the type of drugs being developed and the stages of development.
Trigeminal Neuralgia pipeline comprises of 9 active drugs under active development as of April 2018. Of these, 4 drugs are in phase 2. Further, 4 drugs are in Pre-clinical stage and 1 drug in research stage.
17 companies are developing the pipeline for Trigeminal Neuralgia. Of this, Biogen Inc and Capnia, Inc. have received orphan drug status for their therapeutic candidates.
To assist researchers and business development managers, VPA Research has come up with a comprehensive report on Trigeminal Neuralgia pipeline. The report provides insights into different therapeutic candidates in preclinical, research, discovery, NDA/IND, pre registration, phase 1, phase 2, and phase 3 trials). Drugs under development directly and through combination with other drugs are also included.
Current status, developmental phase, participating companies and entities, recent developments, orphan drug/fast track/other designations, drug class are provided for each Trigeminal Neuralgia pipeline product. Mechanism of Action and the target area of the pipeline product are also provided. Further, clinical and preclinical trials along with results of the trials are also included in the report.
In addition to complete details of each product, the report provides key trends in Trigeminal Neuralgia pipeline studies. The products under development are categorized according to their development phase, mechanism and company to provide detailed insights into the type of drugs being developed and the stages of development.
1 TABLE OF CONTENTS
1.1 LIST OF FIGURES
1.2 LIST OF TABLES
2 EXECUTIVE SUMMARY
2.1 DISEASE OVERVIEW
2.2 PIPELINE SNAPSHOT
2.3 PIPELINE DRUGS BY PHASE
2.4 PIPELINE DRUGS BY COMPANY
2.5 PIPELINE DRUGS BY MECHANISM OF ACTION
3 TRIGEMINAL NEURALGIA- COMPANY WISE PIPELINE ANALYSIS
3.1 Allodynic Therapeutics, LLC PIPELINE, H1 2018
3.2 Biogen Inc PIPELINE, H1 2018
3.3 Capnia, Inc. PIPELINE, H1 2018
3.4 Grace Therapeutics LLC PIPELINE, H1 2018
3.5 InMed Pharmaceuticals Inc PIPELINE, H1 2018
3.6 KPI Therapeutics, Inc. PIPELINE, H1 2018
3.7 Merz Pharma GmbH & Co. KGaA PIPELINE, H1 2018
3.8 OliPass Corporation PIPELINE, H1 2018
3.9 PixarBio Corporation PIPELINE, H1 2018
4 TRIGEMINAL NEURALGIA DRUG SNAPSHOTS
4.1 BIIB074 DRUG DETAILS
4.1.1 Snapshot
4.1.2 Drug Overview
4.1.3 Mechanism of Action
4.1.4 Current Status
4.1.5 Trial Details
4.2 Nasal CO2 DRUG DETAILS
4.2.1 Snapshot
4.2.2 Drug Overview
4.2.3 Mechanism of Action
4.2.4 Current Status
4.2.5 Trial Details
4.3 GTX-201 DRUG DETAILS
4.3.1 Snapshot
4.3.2 Drug Overview
4.3.3 Mechanism of Action
4.3.4 Current Status
4.4 INM-405 DRUG DETAILS
4.4.1 Snapshot
4.4.2 Drug Overview
4.4.3 Mechanism of Action
4.4.4 Current Status
4.5 CSP-4 DRUG DETAILS
4.5.1 Snapshot
4.5.2 Drug Overview
4.5.3 Mechanism of Action
4.5.4 Current Status
4.6 incobotulinumtoxinA DRUG DETAILS
4.6.1 Snapshot
4.6.2 Drug Overview
4.6.3 Mechanism of Action
4.6.4 Current Status
4.6.5 Trial Details
4.7 OLP-1002 DRUG DETAILS
4.7.1 Snapshot
4.7.2 Drug Overview
4.7.3 Mechanism of Action
4.7.4 Current Status
4.8 NeuroRelease NR14 DRUG DETAILS
4.8.1 Snapshot
4.8.2 Drug Overview
4.8.3 Mechanism of Action
4.8.4 Current Status
4.9 ALLOD-2 DRUG DETAILS
4.9.1 Snapshot
4.9.2 Drug Overview
4.9.3 Mechanism of Action
4.9.4 Current Status
5 RECENT DEVELOPMENTS IN TRIGEMINAL NEURALGIA PIPELINE
5.1 Capnia Granted Orphan Designation for Nasal CO2 for the Treatment of Trigeminal Neuralgia- 2015
5.2 InMed Pharmaceuticals, Inc. Updates Pain Program- 2017
5.3 Merz and Teijin Announce Partnership to Bring Xeomin® (incobotulinumtoxinA) to Japan - 2017
5.4 PixarBio Corporation Clarifies Pathways to FDA Approval for NR14 to Treat “Trigeminal Neuralgia” and Post-Surgical Pain - 2018
6 APPENDIX
6.1 ABOUT VPA RESEARCH
6.2 SOURCES AND RESEARCH METHODOLOGY
1.1 LIST OF FIGURES
1.2 LIST OF TABLES
2 EXECUTIVE SUMMARY
2.1 DISEASE OVERVIEW
2.2 PIPELINE SNAPSHOT
2.3 PIPELINE DRUGS BY PHASE
2.4 PIPELINE DRUGS BY COMPANY
2.5 PIPELINE DRUGS BY MECHANISM OF ACTION
3 TRIGEMINAL NEURALGIA- COMPANY WISE PIPELINE ANALYSIS
3.1 Allodynic Therapeutics, LLC PIPELINE, H1 2018
3.2 Biogen Inc PIPELINE, H1 2018
3.3 Capnia, Inc. PIPELINE, H1 2018
3.4 Grace Therapeutics LLC PIPELINE, H1 2018
3.5 InMed Pharmaceuticals Inc PIPELINE, H1 2018
3.6 KPI Therapeutics, Inc. PIPELINE, H1 2018
3.7 Merz Pharma GmbH & Co. KGaA PIPELINE, H1 2018
3.8 OliPass Corporation PIPELINE, H1 2018
3.9 PixarBio Corporation PIPELINE, H1 2018
4 TRIGEMINAL NEURALGIA DRUG SNAPSHOTS
4.1 BIIB074 DRUG DETAILS
4.1.1 Snapshot
4.1.2 Drug Overview
4.1.3 Mechanism of Action
4.1.4 Current Status
4.1.5 Trial Details
4.2 Nasal CO2 DRUG DETAILS
4.2.1 Snapshot
4.2.2 Drug Overview
4.2.3 Mechanism of Action
4.2.4 Current Status
4.2.5 Trial Details
4.3 GTX-201 DRUG DETAILS
4.3.1 Snapshot
4.3.2 Drug Overview
4.3.3 Mechanism of Action
4.3.4 Current Status
4.4 INM-405 DRUG DETAILS
4.4.1 Snapshot
4.4.2 Drug Overview
4.4.3 Mechanism of Action
4.4.4 Current Status
4.5 CSP-4 DRUG DETAILS
4.5.1 Snapshot
4.5.2 Drug Overview
4.5.3 Mechanism of Action
4.5.4 Current Status
4.6 incobotulinumtoxinA DRUG DETAILS
4.6.1 Snapshot
4.6.2 Drug Overview
4.6.3 Mechanism of Action
4.6.4 Current Status
4.6.5 Trial Details
4.7 OLP-1002 DRUG DETAILS
4.7.1 Snapshot
4.7.2 Drug Overview
4.7.3 Mechanism of Action
4.7.4 Current Status
4.8 NeuroRelease NR14 DRUG DETAILS
4.8.1 Snapshot
4.8.2 Drug Overview
4.8.3 Mechanism of Action
4.8.4 Current Status
4.9 ALLOD-2 DRUG DETAILS
4.9.1 Snapshot
4.9.2 Drug Overview
4.9.3 Mechanism of Action
4.9.4 Current Status
5 RECENT DEVELOPMENTS IN TRIGEMINAL NEURALGIA PIPELINE
5.1 Capnia Granted Orphan Designation for Nasal CO2 for the Treatment of Trigeminal Neuralgia- 2015
5.2 InMed Pharmaceuticals, Inc. Updates Pain Program- 2017
5.3 Merz and Teijin Announce Partnership to Bring Xeomin® (incobotulinumtoxinA) to Japan - 2017
5.4 PixarBio Corporation Clarifies Pathways to FDA Approval for NR14 to Treat “Trigeminal Neuralgia” and Post-Surgical Pain - 2018
6 APPENDIX
6.1 ABOUT VPA RESEARCH
6.2 SOURCES AND RESEARCH METHODOLOGY
LIST OF FIGURES
Figure 1: Trigeminal Neuralgia Pipeline by Phase, H1- 2018
Figure 2: Trigeminal Neuralgia Pipeline by Companies, H1- 2018
Figure 3: Company wise Pipeline Drug Phases, H1- 2018
Figure 4: Trigeminal Neuralgia Pipeline by Mechanism of Action, H1- 2018
Figure 5: Mechanism wise Pipeline Drug Phases, H1- 2018
Figure 1: Trigeminal Neuralgia Pipeline by Phase, H1- 2018
Figure 2: Trigeminal Neuralgia Pipeline by Companies, H1- 2018
Figure 3: Company wise Pipeline Drug Phases, H1- 2018
Figure 4: Trigeminal Neuralgia Pipeline by Mechanism of Action, H1- 2018
Figure 5: Mechanism wise Pipeline Drug Phases, H1- 2018
LIST OF TABLES
Table 1: Trigeminal Neuralgia Pipeline by Phase, H1- 2018
Table 2: Trigeminal Neuralgia Pipeline by Companies, H1- 2018 (1)
Table 3: Trigeminal Neuralgia Pipeline by Mechanism of Action, H1- 2018
Table 4: Allodynic Therapeutics, LLC Trigeminal Neuralgia Pipeline, H1- 2018
Table 5: Biogen Inc - Trigeminal Neuralgia Pipeline, H1- 2018
Table 6: Capnia, Inc. Trigeminal Neuralgia Pipeline, H1- 2018
Table 7: Grace Therapeutics LLC - Trigeminal Neuralgia Pipeline, H1- 2018
Table 8: InMed Pharmaceuticals Inc Trigeminal Neuralgia Pipeline, H1- 2018
Table 9: KPI Therapeutics, Inc. - Trigeminal Neuralgia Pipeline, H1- 2018
Table 10: Merz Pharma GmbH & Co. KGaA Trigeminal Neuralgia Pipeline, H1- 2018
Table 11: OliPass Corporation - Trigeminal Neuralgia Pipeline, H1- 2018
Table 12: PixarBio Corporation Trigeminal Neuralgia Pipeline, H1- 2018
Table 1: Trigeminal Neuralgia Pipeline by Phase, H1- 2018
Table 2: Trigeminal Neuralgia Pipeline by Companies, H1- 2018 (1)
Table 3: Trigeminal Neuralgia Pipeline by Mechanism of Action, H1- 2018
Table 4: Allodynic Therapeutics, LLC Trigeminal Neuralgia Pipeline, H1- 2018
Table 5: Biogen Inc - Trigeminal Neuralgia Pipeline, H1- 2018
Table 6: Capnia, Inc. Trigeminal Neuralgia Pipeline, H1- 2018
Table 7: Grace Therapeutics LLC - Trigeminal Neuralgia Pipeline, H1- 2018
Table 8: InMed Pharmaceuticals Inc Trigeminal Neuralgia Pipeline, H1- 2018
Table 9: KPI Therapeutics, Inc. - Trigeminal Neuralgia Pipeline, H1- 2018
Table 10: Merz Pharma GmbH & Co. KGaA Trigeminal Neuralgia Pipeline, H1- 2018
Table 11: OliPass Corporation - Trigeminal Neuralgia Pipeline, H1- 2018
Table 12: PixarBio Corporation Trigeminal Neuralgia Pipeline, H1- 2018
